Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells

Ju‐Hee Lee(Dongguk University), Yung‐Jue Bang(Seoul National University), Yeonjoo Jung(Korea University of Science and Technology), Jee-Hyun Kim(Seoul National University Bundang Hospital), Hyun-Soon Jong, Jung‐Hyun Park(Ewha Womans University), Tae‐You Kim(Seoul National University of Science and Technology)
Molecular Cancer Therapeutics
December 1, 2006
10.1158/1535-7163.mct-06-0419
Cited by 100

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
|Nature Cell Biology|2000|1.6k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k